A federal judge in Texas refuted four key patents for the dry-eye treatment Restasis inflicting a blow to its manufacturer Allergan which had solicited to safeguard its patents by shifting them to a Native American tribe.

The pronouncement by United States Circuit Judge William C. Bryson of the Eastern District of Texas doesn’t signify that generic adaptation of the drug will be obtainable soon. Allergen said that it would plead the settlement and the Food and Drug Administration has yet not endorsed copycat category of the drugs.

Still the resolution was disappointment for the company whose stock plunged more than five percent on the news. Restasis is Allergan’s second very successful product, following the wrinkle treatment Botox, collating nearly $1.5 billion in 2016.

In September Allergen deviated from its normal course of paying the Saint Regis Mohawk Tribe in upstate New York to ownership of the patents which were then let out back to the company. The strategy was a method to safeguard the company from a patent summons not related to the federal court case that is in progress in an administrative proceeding prior to a unit of the United States Patent and Trademark Office.

The Mohawk tribe has professed that monarch impunity protects the patents for provocation below that process. Allergen’s protocol with the tribe did not expand to the legal confrontation playing out in the Eastern District of Texas, where processors of the generic drugs, involving Teva Pharmaceuticals and Mylan, are also battling Allergan over the reasonableness of the patents.